Status:
COMPLETED
Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304
Lead Sponsor:
GlaxoSmithKline
Conditions:
Epilepsy, Partial
Eligibility:
All Genders
18-75 years
Brief Summary
The objective of this meta-analysis is to provide data on long-term safety and efficacy following the recent positive Committee for Medicinal Products for Human Use (CHMP) opinion for retigabine using...
Detailed Description
Data from the October 2009 data-cut of ongoing Studies VRX-RET-E22-303 (Study 303) and VRX-RET-E22-304 (Study 304) will be pooled, summarized, and published with the goal of providing updated long-ter...
Eligibility Criteria
Inclusion
- This is meta-analysis therefore Inclusion/Exclusion criteria are not applicable.
Exclusion
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01457989
Start Date
August 1 2011
End Date
August 1 2011
Last Update
October 29 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.